CBD producers and retailers in the UK began receiving letters from the Medicines and Healthcare Products Regulatory Agency informing them of a recent decision by the agency to classify CBD (cannabidiol) as medicine. CBD businesses in the UK were given 28 days to stop selling or promoting CBD products. According to a statement published on Voltface, the MHRA provided the following statement regarding their decision:
If you use CBD and if you have any questions, speak to your GP or other healthcare professional.
We have written to UK CBD stockists and manufacturers to inform them of our view. These products will require a marketing authorisation to be granted before they can be legally sold, supplied or anywhere advertised in the UK. We can provide regulatory guidance to any company who may wish to apply for a licence.”
Paving the way for big pharma
The MHRA’s announcement should come as no surprise to activists, both in the UK and the US, who have watched UK-based GW Pharmaceuticals get closer and closer to official approval of their cannabis-based drugs over the last two years. Just a little over a week ago GW Pharmaceuticals released the results of their most recent clinical trial for Epidolex, which is a cannabis-based CBD drug aimed at treating children with Dravet Syndrome, Lennox-Gastaut Syndrome and other conditions that cause intractable seizures.